JP2024516187A - 幹細胞機能を向上させるためのウロリチン - Google Patents

幹細胞機能を向上させるためのウロリチン Download PDF

Info

Publication number
JP2024516187A
JP2024516187A JP2023565251A JP2023565251A JP2024516187A JP 2024516187 A JP2024516187 A JP 2024516187A JP 2023565251 A JP2023565251 A JP 2023565251A JP 2023565251 A JP2023565251 A JP 2023565251A JP 2024516187 A JP2024516187 A JP 2024516187A
Authority
JP
Japan
Prior art keywords
urolithin
cells
stem cell
hspcs
uroa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023565251A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516187A5 (https=
Inventor
ムクル ギロトラ，
ニコラ ヴァンニーニ，
Original Assignee
ソシエテ・デ・プロデュイ・ネスレ・エス・アー
ルドウイグ インスティテュート フォー キャンサー リサーチ エルティーディー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ソシエテ・デ・プロデュイ・ネスレ・エス・アー, ルドウイグ インスティテュート フォー キャンサー リサーチ エルティーディー filed Critical ソシエテ・デ・プロデュイ・ネスレ・エス・アー
Publication of JP2024516187A publication Critical patent/JP2024516187A/ja
Publication of JP2024516187A5 publication Critical patent/JP2024516187A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Primary Cells (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023565251A 2021-05-05 2022-05-02 幹細胞機能を向上させるためのウロリチン Pending JP2024516187A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21172290 2021-05-05
EP21172290.5 2021-05-05
PCT/EP2022/061666 WO2022233767A1 (en) 2021-05-05 2022-05-02 Urolithin for increasing stem cell function

Publications (2)

Publication Number Publication Date
JP2024516187A true JP2024516187A (ja) 2024-04-12
JP2024516187A5 JP2024516187A5 (https=) 2025-05-16

Family

ID=75825544

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565251A Pending JP2024516187A (ja) 2021-05-05 2022-05-02 幹細胞機能を向上させるためのウロリチン

Country Status (8)

Country Link
US (1) US20240228966A1 (https=)
EP (1) EP4333832A1 (https=)
JP (1) JP2024516187A (https=)
CN (1) CN117202903A (https=)
AU (1) AU2022270331A1 (https=)
BR (1) BR112023022224A2 (https=)
CA (1) CA3213384A1 (https=)
WO (1) WO2022233767A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723315A (en) 1996-08-23 1998-03-03 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO1998005635A1 (en) 1996-08-07 1998-02-12 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
WO2019163176A1 (ja) * 2018-02-21 2019-08-29 株式会社ダイセル ウロリチン類を含有する破骨細胞分化抑制剤
JP7557374B2 (ja) * 2018-04-30 2024-09-27 アマゼンティス エスアー 免疫増強剤としてのウロリチンａ
JP7677893B2 (ja) * 2019-01-18 2025-05-15 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 幹細胞機能を向上させるための薬剤及び方法

Also Published As

Publication number Publication date
EP4333832A1 (en) 2024-03-13
CN117202903A (zh) 2023-12-08
US20240228966A1 (en) 2024-07-11
WO2022233767A1 (en) 2022-11-10
AU2022270331A1 (en) 2023-10-12
CA3213384A1 (en) 2022-11-10
BR112023022224A2 (pt) 2024-02-06
AU2022270331A9 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
JP7677893B2 (ja) 幹細胞機能を向上させるための薬剤及び方法
Hoorweg et al. Functional differences between human NKp44− and NKp44+ RORC+ innate lymphoid cells
IL142094A (en) Method for control and integrity of germ cells and beak
US20240101960A1 (en) Expansion and use of expanded nk cell fractions
Kurtzberg et al. Preclinical characterization of DUOC-01, a cell therapy product derived from banked umbilical cord blood for use as an adjuvant to umbilical cord blood transplantation for treatment of inherited metabolic diseases
JPWO2020158924A1 (ja) 母児間免疫寛容を誘導する方法
JP7295810B2 (ja) 移植に適した臍帯細胞画分の選択と使用
US20240010981A1 (en) Compositions and methods for increasing stem cell function
US20230365933A1 (en) Compositions and methods for increasing stem cell function
JP2024516187A (ja) 幹細胞機能を向上させるためのウロリチン
HK40104930A (zh) 用於增加干细胞功能的尿石素
HK40058827A (en) Agents and methods for increasing stem cell function
WO2010091052A2 (en) Methods for enhancing hematopoietic stem/progenitor cell engraftment
HK40096626A (zh) 用於增加干细胞功能的组合物和方法
HK40095240A (zh) 用於增加干细胞功能的组合物和方法
Kurtzberg et al. Reprint of: Preclinical characterization of DUOC-01, a cell therapy product derived from banked umbilical cord blood for use as an adjuvant to umbilical cord blood transplantation for treatment of inherited metabolic diseases
Imanirad et al. HIF1α is a regulator of hematopoietic progenitor and stem cell development
WO2025240522A2 (en) Modulation of cell activity
Chandrinou et al. Publication only EBMT 2006

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250502

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260428